Explore
Validate
Learn12016-1-AP
antibody from Proteintech Group
Targeting: IKZF1
hIk-1, Hs.54452, IKAROS, LyF-1, PPP1R92, ZNFN1A1
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [14]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12016-1-AP - Provider product page
- Provider
- Proteintech Group
- Proper citation
- Proteintech Cat#12016-1-AP, RRID:AB_2124704
- Product name
- IKZF1 antibody
- Antibody type
- Polyclonal
- Description
- IKZF1 antibody (Cat. #12016-1-AP) is a rabbit polyclonal antibody that shows reactivity with human, mouse, rat and has been validated for the following applications: IHC, IP, WB,ELISA.
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 20ul, 150ul
Submitted references Discovery of the First-in-Class Protein Arginine Methyltransferase 1 PROTAC Degrader.
GSPT1-specific protein degradation is effective in preclinical models of chemoresistant MYCN-amplified neuroblastoma.
Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines.
IKZF1 exacerbates the inflammatory response by epigenetically modulating mitochondrial function following acute peritonitis.
Discovery of degrader for FLT3, GSPT1 and IKZF1/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia.
Genome-wide rules of transcription factor cooperativity revealed through in silico binding site ablation.
Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
Identification of key genes in salivary gland in Sjögren's syndrome complicated with Hashimoto thyroiditis: Common pathogenesis and potential diagnostic markers.
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.
Discovery of potential novel CRBN modulators by virtual screening and bioassay.
Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia.
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
A Novel Regulatory Mechanism of Smooth Muscle α-Actin Expression by NRG-1/circACTA2/miR-548f-5p Axis.
Guo S, Li J, Lin J, Chen Y, Liu C, Liu H, He Z, Zhu Y, Wang L, Yang F, Luo C, Li Z, Jin J, Ye F
Journal of medicinal chemistry 2026 Mar 26;69(6):6775-6789
Journal of medicinal chemistry 2026 Mar 26;69(6):6775-6789
GSPT1-specific protein degradation is effective in preclinical models of chemoresistant MYCN-amplified neuroblastoma.
Adamska A, Chahin H, Muciño-Olmos EA, Esfandyari J, Aaltonen K, Granados-Aparici S, Siaw JT, Radke K, Lago C, Pasikowski P, Pluta R, Sawicka A, Glaza P, Gisselsson D, Navarro S, Noguera R, Majkut J, Dobrzański P, Cottens S, Walczak MJ, Bexell D
Journal of experimental & clinical cancer research : CR 2026 Feb 6;45(1):58
Journal of experimental & clinical cancer research : CR 2026 Feb 6;45(1):58
Discovery and Characterization of Novel IKZF1/3 Glue Degraders against Multiple Hematological Cancer Cell Lines.
Wei T, Wei P, Wang Y, Mao Y, Yan J, Hu X, Qi Z, Cai X, Jia C, Zhao Z, Li B, Qiao M, Zou Y, Yang T, Sun S, Feng X, Li P, Shang H, Zheng Z
Oncology research 2025;33(10):2981-3006
Oncology research 2025;33(10):2981-3006
IKZF1 exacerbates the inflammatory response by epigenetically modulating mitochondrial function following acute peritonitis.
Liu G, Hu P, Dong Y, Xu Y, Yang Z, Qi Z, Su Y
Frontiers in immunology 2025;16:1600903
Frontiers in immunology 2025;16:1600903
Discovery of degrader for FLT3, GSPT1 and IKZF1/3 proteins merging PROTAC and molecular glue targeting FLT3-ITD mutant acute myeloid leukemia.
Yang Y, Yao Q, Song D, Tang K, Tang Z, Hu M, Luo Y, Xie Y
European journal of medicinal chemistry 2025 Oct 15;296:117893
European journal of medicinal chemistry 2025 Oct 15;296:117893
Genome-wide rules of transcription factor cooperativity revealed through in silico binding site ablation.
He X, Einarsson H, Páleníková P, Rennie S, Hu D, Cui R, Vaagensø C, Lage K, Krautz R, Andersson R
bioRxiv : the preprint server for biology 2025 Jun 24;
bioRxiv : the preprint server for biology 2025 Jun 24;
Decreased RNA-binding protein heterogeneous nuclear ribonucleoprotein U improves multiple myeloma sensitivity to lenalidomide.
Lin Z, Zhang Y, Liu X, Luo H, Li Q, Gao Q, Wang X, Wen J, Li L, Feng Y, Wang F, Huang J, Zhai X, Zhang L, Niu T, Zheng Y
British journal of haematology 2024 Aug;205(2):594-606
British journal of haematology 2024 Aug;205(2):594-606
Identification of key genes in salivary gland in Sjögren's syndrome complicated with Hashimoto thyroiditis: Common pathogenesis and potential diagnostic markers.
Zhang K, Yu X, Zhang Y, Lu D, Yao X, Hong T, Ren Y, Chen L, Wang X
Medicine 2023 Sep 29;102(39):e35188
Medicine 2023 Sep 29;102(39):e35188
Discovery of novel BTK PROTACs with improved metabolic stability via linker rigidification strategy.
Chen S, Chen Z, Lu L, Zhao Y, Zhou R, Xie Q, Shu Y, Lin J, Yu X, Wang Y
European journal of medicinal chemistry 2023 Jul 5;255:115403
European journal of medicinal chemistry 2023 Jul 5;255:115403
Discovery of potential novel CRBN modulators by virtual screening and bioassay.
Xiong F, Kong L, Chen L, Xue M, Cao F, Zhang S, Li H, Yan H, Li Y, Zuo Z
European journal of medicinal chemistry 2022 Jun 5;236:114355
European journal of medicinal chemistry 2022 Jun 5;236:114355
Mechanistic Basis for In Vivo Therapeutic Efficacy of CK2 Inhibitor CX-4945 in Acute Myeloid Leukemia.
Klink M, Rahman MA, Song C, Dhanyamraju PK, Ehudin M, Ding Y, Steffens S, Bhadauria P, Iyer S, Aliaga C, Desai D, Huang S, Claxton D, Sharma A, Gowda C
Cancers 2021 Mar 5;13(5)
Cancers 2021 Mar 5;13(5)
Expression of CRBN, IKZF1, and IKZF3 does not predict lenalidomide sensitivity and mutations in the cereblon pathway are infrequent in multiple myeloma.
Dimopoulos K, Fibiger Munch-Petersen H, Winther Eskelund C, Dissing Sjö L, Ralfkiaer E, Gimsing P, Grønbaek K
Leukemia & lymphoma 2019 Jan;60(1):180-188
Leukemia & lymphoma 2019 Jan;60(1):180-188
Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a cereblon-independent manner.
Dimopoulos K, Søgaard Helbo A, Fibiger Munch-Petersen H, Sjö L, Christensen J, Sommer Kristensen L, Asmar F, Hermansen NEU, O'Connel C, Gimsing P, Liang G, Grønbaek K
Molecular oncology 2018 Feb;12(2):180-195
Molecular oncology 2018 Feb;12(2):180-195
A Novel Regulatory Mechanism of Smooth Muscle α-Actin Expression by NRG-1/circACTA2/miR-548f-5p Axis.
Sun Y, Yang Z, Zheng B, Zhang XH, Zhang ML, Zhao XS, Zhao HY, Suzuki T, Wen JK
Circulation research 2017 Sep 1;121(6):628-635
Circulation research 2017 Sep 1;121(6):628-635
No comments: Submit comment
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- HeLa cells were subjected to SDS PAGE followed by western blot with 12016-1-AP(IKZF1 antibody) at dilution of 1:500
- Sample type
- cell line
Supportive validation
- Submitted by
- Proteintech Group (provider)
- Main image
- Experimental details
- The IKZF1 antibody from Proteintech is a rabbit polyclonal antibody to a recombinant protein of human IKZF1. This antibody recognizes human, mouse, rat antigen. The IKZF1 antibody has been validated for the following applications: ELISA, WB, IHC analysis.
